High prevalence of growth hormone deficiency in severe fibromyalgia syndromes

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages 4331-4337

  Cuatrecasas, Guillem ^a   Gonzalez, M J ^b   Alegre, C ^b   Sesmilo, G ^b   Fernandez Sola J ^c   Casanueva, F F ^d   Garcia Fructuoso, F ^e   Poca Dias, V ^e   Izquierdo, J P ^f   Puig Domingo, M ^c  

^a CENTRO MÉDICO TEKNON   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e Rheumatology Department   (Spain)

^f Biomedical Research Laboratory   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; GROWTH HORMONE; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN; TRAMADOL; HUMAN GROWTH HORMONE; INSULIN; SOMATOMEDIN C;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FIBROMYALGIA; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE SENSITIVITY; HUMAN; INSULIN TOLERANCE TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; TERTIARY HEALTH CARE; BIOLOGICAL MODEL; BLOOD; COMPLICATION; DEFICIENCY; HYPOPITUITARISM; MIDDLE AGED; PREVALENCE; SEVERITY OF ILLNESS INDEX; SYNDROME;

ADULT; BODY MASS INDEX; COHORT STUDIES; FEMALE; FIBROMYALGIA; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; MODELS, BIOLOGICAL; PREVALENCE; SEVERITY OF ILLNESS INDEX; SYNDROME;

EID: 77956575225     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0061     Document Type: Article

References (38)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, Mccain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP 1990 The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160-172
2. Martínez-Lavín M 2001 Overlap of fibromyalgia with other medical conditions. Curr Pain Headache Rep 5:347-350
3. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ 2003 Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 30:1318-1325
4. Collado A, Alijotas J, Benito P, Alegre C, Romera M, Sañudo I, Martín R, Peri JM, Cots JM 2002 Consensus report on the diagnosis and treatment of fibromyalgia in Catalonia. Med Clin (Barc) 118:745-749
5. Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, Gracely RH, Clauw DJ 2003 Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 48:2916-2922
6. Staud R, Robinson ME, Price DD 2007 Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J Pain 8:893-901
7. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK 2007 Decreased central μ-opioid receptor availability in fibromyalgia. J Neurosci 27:10000-10006
8. Emad Y, Ragab Y, Zeinhom F, El-Khouly G, Abou-Zeid A, Rasker JJ 2008 Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome. A study with single-voxel magnetic resonance spectroscopy. J Rheumatol 35:1371-1377
9. Bennett RM 1989 Beyond fibromyalgia: ideas on etiology and treatment. J Rheumatol Suppl 19:185-191
10. Buskila D, Sarzi-Puttini P 2008 Fibromyalgia and autoimmune diseases: the pain behind autoimmunity. Isr Med Assoc J 10:77-78
11. Cuatrecasas G 2009 Fibromyalgic syndromes: could growth hormone therapy be beneficial? Pediatr Endocrinol Rev 6(Suppl 4):529-533
12. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D 1998 The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-deficient adults. J Clin Endocrinol Metab 83:107-116
13. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM 1997 Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 24:1384-1389
14. Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva H, Garcia-Pesquera F, Casanueva FF, Dieguez C 1999 The growth hormone (GH)-releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab 84:3378-3381
15. Denko CW, Malemud CJ 2005 Serum growth hormone and insulin but not insulin-like growth factor-1 levels are elevated in patients with fibromyalgia syndrome. Rheumatol Int 25:146-151
16. Yuen KC, Bennett RM, Hryciw CA, Cook MB, Rhoads SA, Cook DM 2007 Is further evaluation for growth hormone (GH) deficiency necessary in fibromyalgia patients with low serum insulin-like growth factor (IGF)-I levels? Growth Horm IGF Res 17:82-88
17. Paiva ES, Deodhar A, Jones KD, Bennett R 2002 Impaired growth hormone secretion in fibromyalgia patients: evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum 46:1344-1350
18. Ferraccioli G, Guerra P, Rizzi V, Baraldo M, Salaffi F, Furlanut M, Bartoli E 1994 Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. J Rheumatol 21:1332-1334
19. Griep EN, Boersma JW, de Kloet ER 1994 Pituitary release of growth hormone and prolactin in the primary fibromyalgia syndrome. J Rheumatol 21:2125-2130
20. Dinser R, Halama T, Hoffmann A 2000 Stringent endocrinological testing reveals subnormal growth hormone secretion in some patients with fibromyalgia syndrome but rarely severe growth hormone deficiency. J Rheumatol 27:2482-2488
21. McCall-Hosenfeld JS, Goldenberg DL, Hurwitz S, Adler GK 2003 Growth hormone and insulin-like growth factor-1 concentrations in women with fibromyalgia. J Rheumatol 30:809-814
22. Bennett RM, Clark SC, Walczyk J 1998 A randomized, double-blind, placebo controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 104:227-231
23. Cuatrecasas G, Riudavets C, Güell MA, Nadal A 2007 Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskelet Disord 8:119
24. Esteve-Vives J, Rivera J, Salvat MI, De Gracia M, Alegre C 2007 Proposal for a consensus version of the fibromyalgia impact questionnaire (FIQ) for the Spanish population. Reumatol Clin 3:21-24
25. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML 2002 Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 87:2067-2079
26. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML, Stephens PA 2006 Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91:1621-1634
27. Conceição FL, da Costa e Silva A, Leal Costa AJ, Vaisman M 2003 Glucagon stimulation test for the diagnosis of GH deficiency in adults. J Endocrinol Invest 26:1065-1070
28. Likitmaskul S, Watcharasindhu S, Angsusingha K, Chaichanwatanakul K, Punnakunta L, Tuchinda C 1998 IGF-1 generation test in non-growth hormone-deficient short children. Horm Res 49(Suppl 1):52
29. Gleeson HK, Shalet SM 2005 GH responsiveness varies during the menstrual cycle. Eur J Endocrinol 153:775-779
30. Gasco V, Corneli G, Rovere S, Croce C, Beccuti G, Mainolfi A, Grottoli S, Aimaretti G, Ghigo E 2008 Diagnosis of adult GH deficiency. Pituitary 11:121-128
31. Delitala G, Tomasi PA, Palermo M, Ross RJ, Grossman A, Besser GM 1989 Opioids stimulate growth hormone (GH) release in man independently of GH-releasing hormone. J Clin Endocrinol Metab 69:356-358
32. Corneli G, Ghigo E, Aimaretti G 2007 Managing patients with hypopituitarisn after traumatic brain injury. Curr Opin Endocrinol Diabetes Obes 14:301-305 (Pubitemid 47067115)
33. Leal-Cerro A, Rincón MD, Domingo MP 2009 Disfunción Neuroendocrina y Agresión Cerebral de la Sociedad Española de Endocrinología y Nutrición (SEEN). Neuroendocrine dysfunction and brain injury. A consensus statement. Endocrinol Nutr 56:293-302
34. McNab TL, Khandwala HM 2005 Acromegaly as an endocrine form of myopathy: case report and review of literature. Endocr Pract 11:18-22
35. Van den Berghe G 2002 Endocrinology in intensive care medicine: new insights and therapeutic consequences. Verh K Acad Geneeskd Belg 64:167-187; discussion 187-188
36. Martel-Pelletier J, Di Battista JA, Lajeunesse D, Pelletier JP 1998 IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis. Inflamm Res 47:90-100
37. Massicotte F, Fernandes JC, Martel-Pelletier J, Pelletier JP, Lajeunesse D 2006 Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone 38:333-341 (Pubitemid 43255427)
38. Cook DM 2004 Growth hormone and estrogen: a clinician's approach. J Pediatr Endocrinol Metab 17(Suppl 4):1273-1276